Literature DB >> 19834516

Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

S Prabhakar1, G J Brenner, B Sung, S M Messerli, J Mao, M Sena-Esteves, A Stemmer-Rachamimov, B Tannous, X O Breakefield.   

Abstract

Schwannomas are benign tumors forming along peripheral nerves that can cause deafness, pain and paralysis. Current treatment involves surgical resection, which can damage associated nerves. To achieve tumor regression without damage to nerve fibers, we generated an HSV amplicon vector in which the apoptosis-inducing enzyme, caspase-1 (ICE), was placed under the Schwann cell-specific P0 promoter. Infection of schwannoma, neuroblastoma and fibroblastic cells in culture with ICE under the P0 promoter showed selective toxicity to schwannoma cells, while ICE under a constitutive promoter was toxic to all cell types. After direct intratumoral injection of the P0-ICE amplicon vector, we achieved marked regression of schwannoma tumors in an experimental xenograft mouse model. Injection of this amplicon vector into the sciatic nerve produced no apparent injury to the associated dorsal root ganglia neurons or myelinated nerve fibers. The P0-ICE amplicon vector provides a potential means of 'knifeless resection' of schwannoma tumors by injection of the vector into the tumor with low risk of damage to associated nerve fibers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834516      PMCID: PMC2857743          DOI: 10.1038/cgt.2009.71

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  43 in total

1.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.

Authors:  I Galve-Roperh; C Sánchez; M L Cortés; T Gómez del Pulgar; M Izquierdo; M Guzmán
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  A novel imaging-compatible sciatic nerve schwannoma model.

Authors:  Okay Saydam; Gokhan Baris Ozdener; Ozlem Senol; Arda Mizrak; Shilpa Prabhakar; Anat O Stemmer-Rachamimov; Xandra O Breakefield; Gary J Brenner
Journal:  J Neurosci Methods       Date:  2010-11-24       Impact factor: 2.390

4.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

5.  Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells.

Authors:  J Hewett; C Gonzalez-Agosti; D Slater; P Ziefer; S Li; D Bergeron; D J Jacoby; L J Ozelius; V Ramesh; X O Breakefield
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

6.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

7.  Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.

Authors:  S Prabhakar; S M Messerli; A O Stemmer-Rachamimov; T-C Liu; S Rabkin; R Martuza; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2007-02-16       Impact factor: 5.987

8.  Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.

Authors:  Nancy Kemeny; Karen Brown; Anne Covey; Teresa Kim; Amit Bhargava; Lynn Brody; Brenda Guilfoyle; Natasha P Haag; Matthias Karrasch; Birgit Glasschroeder; Anette Knoll; George Getrajdman; K Jon Kowal; William R Jarnagin; Yuman Fong
Journal:  Hum Gene Ther       Date:  2006-12       Impact factor: 5.695

9.  Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

Authors:  Gene Hung; Xiankui Li; Rodolfo Faudoa; Zhu Xeu; Lan Kluwe; Johng S Rhim; William Slattery; David Lim
Journal:  Int J Oncol       Date:  2002-03       Impact factor: 5.650

10.  Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Authors:  Scott R Plotkin; Marybeth A Singh; Caroline C O'Donnell; Gordon J Harris; Andrea I McClatchey; Chris Halpin
Journal:  Nat Clin Pract Oncol       Date:  2008-06-17
View more
  6 in total

Review 1.  Cancer imaging: Gene transcription-based imaging and therapeutic systems.

Authors:  Hyo-eun C Bhang; Martin G Pomper
Journal:  Int J Biochem Cell Biol       Date:  2012-02-10       Impact factor: 5.085

2.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

3.  Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

Authors:  Shilpa Prabhakar; Roberta L Beauchamp; Pike See Cheah; Akiko Yoshinaga; Edwina Abou Haidar; Sevda Lule; Gayathri Mani; Katia Maalouf; Anat Stemmer-Rachamimov; David H Jung; D Bradley Welling; Marco Giovannini; Scott R Plotkin; Casey A Maguire; Vijaya Ramesh; Xandra O Breakefield
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

4.  Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.

Authors:  Justin C Roth; Kevin A Cassady; James J Cody; Jackie N Parker; Kathleen H Price; Jennifer M Coleman; James O Peggins; Patricia E Noker; Nicholas W Powers; Sheila D Grimes; Steven L Carroll; G Yancey Gillespie; Richard J Whitley; James M Markert
Journal:  Hum Gene Ther Clin Dev       Date:  2014-03       Impact factor: 5.032

5.  Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth.

Authors:  Arda Mizrak; Mehmet Fatih Bolukbasi; Gokhan Baris Ozdener; Gary J Brenner; Sibylle Madlener; Erdogan Pekcan Erkan; Thomas Ströbel; Xandra O Breakefield; Okay Saydam
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

6.  Schwannoma Gene Therapy via Adeno-Associated Viral Vector Delivery of Apoptosis-Associated Speck-like Protein Containing CARD (ASC): Preclinical Efficacy and Safety.

Authors:  Sherif G Ahmed; Casey A Maguire; Shiliang Alice Cao; Gary J Brenner
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.